China Pharma Gets Green Light for Antibiotics Trial

| About: China Pharma (CPHI)

China Pharma Holdings (NYSEMKT:CPHI) was given the go-ahead by the SFDA to begin clinical trials of a novel antibiotic combination formula. China Pharma describes the new product as a third generation Cephalosporin antibiotic combined with a bacterial-enzyme inhibitor. Its clinical trial will begin in November.

China Pharma expects to conclude clinical tests of the drug in two years. The company said its early work with the product showed it was effective against resistant strains of bacteria. The company hopes it will eventually gain market share against infections, including hospital-acquired and respiratory infections, bacterial meningitis, and pneumonia.

China Pharma says that in 2005 between 20% and 70% of pathogen strains have shown resistance to one or more third-generation Cephalosporins. The market for Cephalosporins in China is predicted to top 38 billion RMB ($5.6 billion) in 2008, up 50% from 25 billion RMB ($3.7 billion) in 2006.

Disclosure: none.